sleepingpanda / Shutterstock.com
Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.
The Patent Law of the People’s Republic of China first went into effect on April 1, 1985. It has been amended three times with a fourth amendment scheduled to take effect on June 1, 2021.
The Chinese patent system includes an invention patent, similar to the utility patent of the US. The invention patent application is substantively examined by patent examiners to determine if the invention is novel, inventive, and has “practical applicability”.
The author found that personal interviews with Chinese patent examiners can be effective in advancing prosecution because many examination problems are the result of translation confusion.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Virology, remdesivir, patent laws, Wuhan, novel, utility model, biotechnology, FDA, generics, COVID-19, Gilead